

# Chemcon Specialty Chemicals Ltd. (Chemcon

16<sup>th</sup> November 2021

CMP - ₹390/-

View - Accumulate on dips

### Q2FY22 Update Important Statistics

Chemcon specialty Chemicals' (CHEMCON) topline fell 1% Y-o-Y but was up 7% Q-o-Q to ₹612mn even as sales volumes fell by 21% Y-o-Y.

Domestic: exports contribution stood at 57%:43% in Q2FY22.

EBITDA for the quarter stood at ₹189mn down ~19% Y-o-Y (due to higher operating expenses) however it grew 6% Q-o-Q. EBITDA margins fell by ~698bps Y-o-Y to 30.9% in Q2FY22.

PAT de-grew 7% Y-o-Y to ~₹146mn from ₹156mn in Q2FY21 due to lower operating profitability. PAT margins stood at 23.8% in the quarter vs 25.3% in Q2FY21.

| MCAP (₹ cr)    | 1460          |
|----------------|---------------|
| 52week H/L (₹) | 569.05/383.30 |
| NSE Code       | CHEMCON       |
| BSE Code       | 543233        |

#### **Key Concall Highlights**

- HMDS contributed 31% to total revenue of which 84% contributed from domestic and around 16% from exports. CMIC contributed 35% to total revenues with domestic and export market contributing equally.
- Q2 FY22 total revenue stood at 612mn, domestic market contributed around 57% whereas international market contributed the remaining 43%.
- > Total production volume for the Q2FY22 was at 1420MT as compared to 1788 MT same period last year.
- Management guided plant P8 capacity utilization to be 50% for H2FY22 and for plant P9 capacity utilization to be 50% by Q4FY22 since the products have high demand in domestic and global markets.
- In H1FY22 total revenue stood at ₹1180mn against ₹1070mn of H1FY21. Domestic market contributed around 63% whereas international market contributes around 37% in H1FY22.
- Production volume was at 2849 MT for the H1FY22 against 2765 MT of H1FY21.

#### **Financials**

| Particulars   | FY19  | FY20  | FY21  |
|---------------|-------|-------|-------|
| Net Sales     | 3,033 | 2,621 | 2,435 |
| EBITDA        | 661   | 703   | 811   |
| EBITDA Margin | 21.8% | 26.8% | 33.3% |
| PAT           | 430   | 489   | 564   |
| EPS (₹)       | 13.5  | 15.4  | 16.5  |
| P/E (x)       | 28.8  | 25.4  | 25.3  |
| EV/EBITDA(x)  | 25.9  | 24.4  | 21.2  |
| ROE           | 44.9% | 34.2% | 38.5% |
| ROCE          | 48.9% | 34.6% | 39.5% |
| D/E(x)        | 0.21  | 0.20  | 0.0   |
| ·             |       | •     | ·     |

#### **Key Risks**

- A significant portion of its revenue comes from a few customers and the loss of one or more such customers or a reduction in their demand for products may adversely affect its business and financials
- Company imports majority of its key RM for HMDS from China, which has been its key revenue-contributing segment. Any import related issues due to anti-china movement can affect the supply chain of the business and thereby financials.
- > Promoter 's court dispute remains a overhang on the stock

#### **View**

Chemcon Specialty Chemicals Ltd reported subdued numbers in Q2FY22 on account of lower sales volumes and subdued demand in its user industries. However, we believe it is a temporary blip and company would perform better in H2FY22 on account of import substitution, innovative product development, exploring newer applications (semiconductor, rubber etc) and upcoming capex in H2FY22. Company's strong return ratios and healthy balance sheet strengthens our confidence on the stock. At CMP of ₹390/- Chemcon Specialty Chemicals is commanding a ~25x P/E on FY21 EPS which is at discount to peers such as, Galaxy Surfactants, Sudarshan Chemicals Ltd etc, thus advice investors to Accumulate the stock on dips.





16th November 2021

CMP - ₹390/-

View - Accumulate on dips

#### **Financial Performance**

|               |         |         |         |              | <i>(₹ mn)</i> |
|---------------|---------|---------|---------|--------------|---------------|
| Particulars   | Q2FY22  | Q1FY22  | Q2FY21  | Y-o-Y        | Q-o-Q         |
| Rev           | 612.40  | 572.05  | 615.37  | -0.5%        | 7.1%          |
| EBITDA        | 189.36  | 178.65  | 233.26  | -18.8%       | 6.0%          |
| EBITDA Margin | 30.9%   | 31.2%   | 37.9%   | (698.32 bps) | (30.83bps)    |
| Depreciation  | 15.0    | 15.2    | 13.9    | 8.0%         | -1.0%         |
| EBIT          | 174.332 | 163.462 | 219.340 | -20.5%       | 6.6%          |
| EBIT Margin   | 28.5%   | 28.6%   | 35.6%   | (717.66 bps) | (10.76bps)    |
| Interest      | 1.5     | 2.3     | 11.8    | -87.0%       | -32.2%        |
| Other Income  | 22.5    | 19.4    | 1.4     | 1486.0%      | 15.9%         |
| PBT           | 195.30  | 180.61  | 208.93  | -6.5%        | 8.1%          |
| Tax           | 49.6    | 46.5    | 53.1    | -6.6%        | 6.7%          |
| PAT           | 145.7   | 134.1   | 155.8   | -6.5%        | 8.6%          |
| PAT Margin    | 23.8%   | 25.4%   | 25.3%   | (152.76 bps) | (163.45 bps)  |
| EPS           | 3.98    | 3.66    | 4.25    | -6.5%        | 8.6%          |

Source: Company Filing, Way2wealth Research



## **Chemcon Specialty Chemicals Ltd. (Chemcon**

16th November 2021

CMP - ₹390/-

View - Accumulate on dips

#### Disclaimer

Analyst Certification: I, Yogita Desai, the research analyst and author of this report, hereby certify that the views expressed in this research report accurately reflect our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s), principally responsible for the preparation of this research report, receives compensation based on overall revenues of the company (Way2Wealth Brokers Private Limited, hereinafter referred to as Way2Wealth) and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

It is confirmed that Yogita Desai, the author of this report has not received any compensation from the companies mentioned in the report in the preceding 12 months. Our research professionals are paid in part based on the profitability of Way2Wealth, which include earnings from other business. Neither Way2Wealth nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information contained in this report.

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Way2Wealth is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. The contents of this material are general and are neither comprehensive nor appropriate for every individual and are solely for the informational purposes of the readers. This material does not take into account the specific objectives, financial situation or needs of an individual/s or a Corporate/s or any entity/s.

This research has been prepared for the general use of the clients of the Way2Wealth and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient, you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Way2Wealth will not treat recipients as customers by virtue of their receiving this report. The distribution of this document in other jurisdictions may be restricted by the law applicable in the relevant jurisdictions and persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

The report is based upon information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up to date and it should not be relied upon as such. Way2Wealth or any of its affiliates or employees makes no warranties, either express or implied of any kind regarding any matter pertaining to this report, including, but not limited to warranties of suitability, fitness for a particular purpose, accuracy, timeliness, completeness or non-infringement. We accept no obligation to correct or update the information or opinions in it. Way2Wealth or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. The recipients of this report should rely on their own investigations. In no event shall Way2Wealth be liable for any damages of any kind, including, but not limited to, indirect, special, incidental, consequential, punitive, lost profits, or lost opportunity, whether or not Way2Wealth has advised of the possibility of such damages.

This material contains statements that are forward-looking; such statements are based upon the current beliefs and expectations and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. These uncertainties include but are not limited to: the risk of adverse movements or volatility in the securities markets or in interest or foreign exchange rates or indices; adverse impact from an economic slowdown; downturn in domestic or foreign securities and trading conditions or markets; increased competition; unfavorable political and diplomatic developments; change in the governmental or regulatory policies; failure of a corporate event and such others. This is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular trading strategy. No part of this material may be copied or duplicated in any form by any means or redistributed without the written consent of Way2Wealth. In no event shall any reader publish, retransmit, redistribute or otherwise reproduce any information provided by Way2Wealth in any format to anyone. Way2Wealth and its affiliates, officers, directors and employees including persons involved in the preparation or issuance of this report may from time to time have interest in securities / positions, financial or otherwise in the securities related to the information contained in this report.

To enhance transparency, Way2Wealth has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report.

#### Disclosure of Interest Statement Chemcon Specialty Chemicals Ltd. (Chemcon) as on November 16th, 2021

| Name of the Security                                                   | Chemcon Specialty Chemicals Ltd. (Chemcon) |
|------------------------------------------------------------------------|--------------------------------------------|
| Name of the analyst                                                    | Yogita Desai                               |
| Analysts' ownership of any stock related to the information contained  | NIL                                        |
| Financial Interest                                                     |                                            |
| Analyst:                                                               | No                                         |
| Analyst's Relative : Yes / No                                          | No                                         |
| Analyst's Associate/Firm : Yes/No                                      | No                                         |
| Conflict of Interest                                                   | No                                         |
| Receipt of Compensation                                                | No                                         |
| Way2Wealth ownership of any stock related to the information contained | NIL                                        |
| Broking relationship with company covered                              | NIL                                        |
| Investment Banking relationship with company covered                   | NIL                                        |

This information is subject to change without any prior notice. Way2Wealth reserves at its absolute discretion the right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, Way2Wealth is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.